Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara García-Alonso

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Trends in Cancer|February 17, 2020
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and BeyondSara García-Alonso, Alberto Ocaña, Atanasio Pandiella
Cancer Research|April 15, 2018
Resistance to Antibody-Drug ConjugatesSara García-Alonso, Alberto Ocaña, Atanasio Pandiella
Trends in Pharmacological Sciences|October 4, 2018
Refining Early Antitumoral Drug DevelopmentAlberto Ocaña, Sara García-Alonso, Eitan Amir, et al.
Oncotarget|October 28, 2016
Multisite phosphorylation of P-Rex1 by protein kinase CJuan Carlos Montero, Samuel Seoane, Sara García-Alonso, et al.
Oncotarget|September 4, 2015
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profilingJuan Carlos Montero, Sara García-Alonso, Alberto Ocaña, et al.
Cancer Research|July 9, 2017
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic ActivityCarla Ríos-Luci, Sara García-Alonso, Elena Díaz-Rodríguez, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 17, 2021
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinomaSara García-Alonso, Inés Romero-Pérez, Lucía Gandullo-Sánchez, et al.
Molecular Oncology|March 21, 2022
KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitorsGuillem Paniagua, Harrys K C Jacob, Oksana Brehey, et al.
Plos One|February 6, 2026
RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1Laura de-la-Puente-Ovejero, Ana Fernández-Rodríguez, Sarah Francoz, et al.
Clinical and Translational Medicine|April 8, 2023
The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinibAdrián Sánchez-Fdez, Sofía Matilla-Almazán, Juan Carlos Montero, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Trends in Cancer|February 17, 2020
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and BeyondSara García-Alonso, Alberto Ocaña, Atanasio Pandiella
Cancer Research|April 15, 2018
Resistance to Antibody-Drug ConjugatesSara García-Alonso, Alberto Ocaña, Atanasio Pandiella
Trends in Pharmacological Sciences|October 4, 2018
Refining Early Antitumoral Drug DevelopmentAlberto Ocaña, Sara García-Alonso, Eitan Amir, et al.
Oncotarget|October 28, 2016
Multisite phosphorylation of P-Rex1 by protein kinase CJuan Carlos Montero, Samuel Seoane, Sara García-Alonso, et al.
Oncotarget|September 4, 2015
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profilingJuan Carlos Montero, Sara García-Alonso, Alberto Ocaña, et al.
Cancer Research|July 9, 2017
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic ActivityCarla Ríos-Luci, Sara García-Alonso, Elena Díaz-Rodríguez, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 17, 2021
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinomaSara García-Alonso, Inés Romero-Pérez, Lucía Gandullo-Sánchez, et al.
Molecular Oncology|March 21, 2022
KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitorsGuillem Paniagua, Harrys K C Jacob, Oksana Brehey, et al.
Plos One|February 6, 2026
RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1Laura de-la-Puente-Ovejero, Ana Fernández-Rodríguez, Sarah Francoz, et al.
Clinical and Translational Medicine|April 8, 2023
The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinibAdrián Sánchez-Fdez, Sofía Matilla-Almazán, Juan Carlos Montero, et al.
Pageof 2